UNSPSC 51372302: Alphaprodine

This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 001O2254AC, chemically known as 1,3-dimethyl-4-phenyl-4-propionoxypiperidine but generally known as alphaprodine, which bears US NIH Compound Identifier 6471. Alphaprodine comes in base and hydrochloride forms. European Medicines Agency schedules Alphaprodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05366MIG.

UNSPSC 51372302 Alphaprodine is a Commodity code that in recent state and local activity frames pharmaceutical procurement more broadly than its narrow chemical name suggests. The three recent opportunities posted under this code involve naloxone and drug deactivation systems for public health response, direct-to-manufacturer prescription programs for state employee health plans, and multi-state cooperative purchasing of generic pharmaceuticals and over-the-counter products. The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). Work solicited includes supply of finished pharmaceutical products, negotiation of direct contracting arrangements with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels, and participation in cooperative purchasing networks that aggregate demand across multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota and Oregon). Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023 (note: date appears inconsistent with posting date). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on vendors' capacity to establish direct contracts with self-insured health plans outside traditional PBM and GPO arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with awards effective July 1, 2026. The MMCAP RFP weighted price competitiveness at 75 percent and required compliance with cGMP and Drug Supply Chain Security Act standards.